Dataset Information

Lack of association between the PIN1 promoter -667T>C (rs2233679) polymorphism and cancer risk: Evidence from meta-analysis.

ABSTRACT: Peptidyl-prolylcis-trans isomerase NIMA-interacting 1 (PIN1) is a critical catalyst involved in multiple oncogenic signaling pathways. The PIN1 promoter -667T>C (rs2233679) polymorphism plays a role in cancer risk. The association between PIN1 (-667T>C) polymorphism and cancer risk has been previously investigated. However, the available results are inconclusive. To derive a more precise estimation, a meta-analysis of seven published case-control studies including 4,524 cases with different tumor types and 4,561 controls was performed. Published literature from PubMed and EMBASE was retrieved. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of the association. Overall, the results did not suggest any associations between the PIN1 promoter (-667T>C) polymorphism and cancer susceptibility (OR=1.04, 95% CI: 0.91-1.18 for CC vs. TT; OR=0.98, 95% CI: 0.89-1.09 for TC vs. TT; OR=1.00, 95% CI: 0.91-1.10 for TC/CC vs. TT; OR=1.07, 95% CI: 0.97-1.18 for CC vs. TC/TT). Further stratified analysis by cancer type, ethnicity and sample size did not reveal any significant associations in the genetic models. The results of the present study demonstrate that the PIN1 promoter (-667T>C; rs2233679) polymorphism is not associated with cancer susceptibility.

SUBMITTER: Tao L

PROVIDER: S-EPMC3917761 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Lack of association between the PIN1 promoter -667T>C (rs2233679) polymorphism and cancer risk: Evidence from meta-analysis.

Tao Liangjun L Chen Yisheng Y Tao Lingsong L Kong Jian J Qin Haibo H Zheng Jie J Zou Bin B He Sizhong S

Biomedical reports 20140122 2

Peptidyl-prolylcis-trans isomerase NIMA-interacting 1 (PIN1) is a critical catalyst involved in multiple oncogenic signaling pathways. The PIN1 promoter -667T>C (rs2233679) polymorphism plays a role in cancer risk. The association between PIN1 (-667T>C) polymorphism and cancer risk has been previously investigated. However, the available results are inconclusive. To derive a more precise estimation, a meta-analysis of seven published case-control studies including 4,524 case ...[more]

PMID: 24649100

Similar Datasets

Project description:BackgroundThe Bcl-2-associated X protein (Bax) is a proapoptotic member of the Bcl-2 family known to be activated and upregulated during apoptosis. Single nucleotide polymorphisms (SNPs) in Bax promoter may participate in the process of carcinogenesis by altering its own expression and the cancer related genes. Bax-248G>A polymorphism has been implicated to alter the risk of cancer, but the listed results are inconsistent and inconclusive. In the present study, we performed a meta-analysis to systematically summarize the possible association of this polymorphism with the risk of cancer.MethodologyWe conducted a search of case-control studies on the associations of Bax-248G>A polymorphism with susceptibility to cancer in Pub Med, Science Direct, Wiley Online Library and hand search. Data from all eligible studies based on some key search terms, inclusion and exclusion criteria were extracted for this meta-analysis. Hardy-Weinberg equilibrium (HWE) in controls, power calculation, heterogeneity analysis, Begg's funnel plot, Egger's linear regression test, forest plot and sensitivity analysis were performed in the present study.ResultsCancer risk associated with Bax-248G>A polymorphism was estimated by pooled odds ratios (ORs) and 95% confidence intervals (95% CIs). The pooled ORs were calculated in allele contrast, homozygous comparison, heterozygous comparison, dominant and recessive model. Statistical significance was checked through Z and p-value in forest plot. A total of seven independent studies including 1772 cases and 1708 controls were included in our meta-analysis. Our results showed that neither allele frequency nor genotype distributions of this polymorphism were associated with risk for cancer in any of the genetic model. Furthermore, Egger's test did not show any substantial evidence of publication bias.Conclusions/significanceThis meta-analysis suggests that the Bax-248G>A polymorphism is not an important cancer risk factor. Nevertheless, additional well-designed studies with larger sample size focusing on different ethnicities and cancer types are required to further validate the results.

Project description:Increasing evidence suggests that the DNA repair gene XRCC6 (Ku70) may be critically involved in the aetiology of the human carcinogenesis. Many studies have investigated the association between the rs2267437 polymorphism and cancer susceptibility. However, the results of these studies have been controversial. This meta-analysis was conducted to quantitatively summarize the evidence for a relationship between the rs2267437 polymorphism and cancer risk.Electronic databases, including PUBMED and EMBASE, were searched for publications that met the inclusion criteria. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between the XRCC6 promoter rs2267437 polymorphism and cancer risk in a fixed-effects model (the Mantel-Haenszel method) or a random-effects model (the DerSimonian and Laird method), as appropriate.A total of 13 case-control studies, involving 3675 cases and 4247 controls, investigating the XRCC6 rs2267437 polymorphism and cancer susceptibility were identified for the meta-analysis. The pooled analysis showed that there is a significant relationship between the XRCC6 rs2267437 polymorphism and cancer susceptibility (GG vs. CC: OR=1.28, 95% CI=1.03-1.60). Subgroup analyses based on the cancer type, ethnicity, and source of the controls were also performed, and these results indicated that the XRCC6 promoter rs2267437 polymorphism was associated with cancer risk in breast cancer studies (GG vs. CC: OR=1.79, 95% CI=1.25-2.56; GG vs. CG+CC: OR=1.40, 95% CI=1.01-1.95), in Asian populations (GG vs. CC: OR=1.33, 95% CI=1.01-1.74) and in population-based studies (GG vs. CC: OR=1.57, 95% CI=1.12-2.22; CG vs. CC: OR=1.35, 95% CI=1.11-1.64; GG+CG vs. CC: OR=1.37, 95% CI=1.14-1.65).This meta-analysis suggests that the XRCC6 rs2267437 polymorphism may affect breast cancer susceptibility and increase the risk of cancer in Asian populations and in the general population. It is critical that further large-scale and well-designed studies be conducted to confirm the association between the rs2267437 genotype and cancer risk.

Dataset Information

Lack of association between the PIN1 promoter -667T>C (rs2233679) polymorphism and cancer risk: Evidence from meta-analysis.

Publications

Lack of association between the <i>PIN1</i> promoter -667T>C (rs2233679) polymorphism and cancer risk: Evidence from meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets